相关实验视频

Updated: Jun 18, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

蛋白质酶和PARP1双目标抑制剂用于多发性骨髓瘤:Fluzoparib

Kai Deng¹, Qiongqiong Li², Lina Lu²

¹Department of Orthopedics, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, China.

Biochemistry and biophysics reports

|July 29, 2024

概括

这项研究引入了fluzoparib作为一种用于多发性骨髓瘤 (MM) 的新型双标药物,抑制了多基酶1 (PARP1) 和蛋白质酶. 这种方法旨在克服MM治疗中的耐药性.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

化疗是多发性骨髓瘤 (MM) 的首要治疗方法,但其有效性受到瘤异质性和耐药性的限制.
单向药物往往不能对付像MM这样的复杂癌症,需要开发多向治疗策略.

研究的目的:

确定和评估用于多发性骨髓瘤 (MM) 的新型多向药物.
作为MM的治疗策略,研究聚基酶1 (PARP1) 和20S蛋白酶的双抑制作为MM的治疗策略.

主要方法:

计算机辅助药物发现 (CADD) 用于选针对PARP1和20S蛋白质组的抑制剂.
用分子动力学 (MD) 模拟来分析候选抑制剂与蛋白质酶体的结合相互作用和稳定性.
在体外和体内实验中评估了fluzoparib的双重目标抑制,抗癌疗效和瘤杀伤能力.

主要成果:

弗卢索帕里布被确定为一种新型抑制剂,有可能对PARP1和20S蛋白质组进行双重位抑制.
分子模拟证实了fluzoparib与蛋白质组的结合模式和动态稳定性.
弗卢索帕里布在酶,细胞和动物模型水平上表现出显著的抗髓瘤活性.

结论:

弗卢佐巴里布代表了对多发性骨髓瘤的有前途的新型治疗剂,提供了双目标抑制机制.
这项研究为开发针对各种癌症的多向药物提供了坚实的基础,解决了当前单向疗法的局限性.

关键词:

计算机辅助的药物发现.这种药物是fluzoparib.多重目标药物多重目标药物多发性骨髓瘤是一种多发性骨髓瘤.聚 ((ADP-Ribose) 聚合酶的多种类型

更多相关视频

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are: